Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-43395 |
Synonyms | |
Therapy Description |
Limited information is currently available on BGB-43395, a putative CDK4 inhibitor (Dec 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-43395 | BGB43395|BGB 43395 | CDK4 Inhibitor 17 | Limited information is currently available on BGB-43395, a putative CDK4 inhibitor (Dec 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06120283 | Phase I | BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |